Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody

Biochemical and Biophysical Research Communications

Volumn 357, Issue 4, 2007, Pages 951-956

  Li, Bohua ^a,b   Wang, Hao ^a,b   Zhang, Dapeng ^a   Qian, Weizhu ^a,b   Hou, Sheng ^a,b   Shi, Shu ^a   Zhao, Lei ^a   Kou, Geng ^a   Cao, Zhiguo ^a   Dai, Jianxin ^a   Guo, Yajun ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Shanghai Center for Cell Engineering and Antibody   (China)

Author keywords

Humanization; Immunogenicity; Molecular modeling; Monoclonal antibody; SM5 1

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SM 5; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; COMPLEMENTARITY DETERMINING REGION; COMPUTER ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; HUMANS; LIVER NEOPLASMS; MICE; MODELS, CHEMICAL; MODELS, IMMUNOLOGICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING;

MURINAE;

EID: 34247891493     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.04.039     Document Type: Article

References (29)

1. Schroff R.W., Foon K.A., Beatty S.M., Oldham R.K., and Morgan Jr. AC. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 45 (1985) 879-885
2. Owens R.J., and Young R.J. The genetic engineering of monoclonal antibodies. J. Immunol. Methods 168 (1994) 149-165
3. Winter G., and Harris W.J. Humanized antibodies. Immunol. Today 14 (1993) 243-246
4. Sandhu J.S. Protein engineering of antibodies. Crit. Rev. Biotechnol. 12 (1992) 437-462
5. Morrison S.L., Johnson M.J., Herzenberg L.A., and Oi V.T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81 (1984) 6851-6855
6. Boulianne G.L., Hozumi N., and Shulman M.J. Production of functional chimaeric mouse/human antibody. Nature 312 (1984) 643-646
7. Jaffers G.J., Fuller T.C., Cosimi A.B., Russell P.S., Winn H.J., and Colvin R.B. Monoclonal antibody therapy. Anti-idiotypic and non-antiidiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 41 (1986) 572-578
8. Hesse C.J., Heyse P., Stolk B.J., Balk A.H., Jutte N.H., Mochtar B., and Weimar W. The incidence and quantity of antiidiotypic antibody formation after OKT3 monoclonal therapy in heart-transplant recipients. Transplant. Proc. 22 (1990) 1772-1773
9. Norman D.J. Mechanisms of action and overview of OKT3. Ther. Drug Monit. 17 (1995) 615-620
10. Tsurushita N., Hinton P.R., and Kumar S. Design of humanized antibodies: from anti-Tac to Zenapax. Methods 36 (2005) 69-83
11. Jones P.T., Dear P.H., Foote J., Neuberger M.S., and Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321 (1986) 522-525
12. Riechmann L., Clark M., Waldmann H., and Winter G. Reshaping human antibodies for therapy. Nature 332 (1988) 323-327
13. Queen C., Schneider W.P., Selick H.E., Payne P.W., Landolfi N.F., Duncan J.F., Avdalovic N.M., Levitt M., Junghans R.P., and Waldmann T.A. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA 86 (1989) 10029-10033
14. Pulito V.L., Roberts V.A., Adair J.R., Rothermel A.L., Collins A.M., Varga S.S., Martocello C., Bodmer M., Jolliffe L.K., and Zivin R.A. Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A. J. Immunol. 156 (1996) 2840-2850
15. Nakamura K., Tanaka Y., Shitara K., and Hanai N. Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions. Cancer Immunol. Immunother. 50 (2001) 275-284
16. Kostelny S.A., Link B.K., Tso J.Y., Vasquez M., Jorgensen B.H., Wang H., Hall W.C., and Weiner G.J. Humanization and characterization of the anti-HLA-DR antibody 1D10. Int. J. Cancer 93 (2001) 556-565
17. Kettleborough C.A., Saldanha J., Heath V.J., Morrison C.J., and Bendig M.M. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng. 4 (1991) 773-783
18. Wu H., Nie Y., Huse W.D., and Watkins J.D. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J. Mol. Biol. 294 (1999) 151-162
19. Trefzer U., Rietz N., Chen Y., Audring H., Herberth G., Siegel P., Reinke S., Koniger P., Wu S., Ma J., Liu Y., Wang H., Sterry W., and Guo Y. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions. Arch. Dermatol. Res. 292 (2000) 583-589
20. Trefzer U., Hofmann M., Reinke S., Guo Y.J., Audring H., Spagnoli G., and Sterry W. Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy. Melanoma. Res. 16 (2006) 137-145
21. Reinke S., Koniger P., Herberth G., Audring H., Wang H., Ma J., Guo Y., Sterry W., and Trefzer U. Differential expression of MART-1, tyrosinase, and SM5-1 in primary and metastatic melanoma. Am. J. Dermatopathol. 27 (2005) 401-406
22. H. Wang, S. Song, G. Kou, B. Li, D. Zhang, S. Hou, W.Qian, J. Dai, L. Tian, J. Zhao, Y. Guo, Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome. Cancer Immunol. Immunother. (2007), doi:10.1007/s00262-007-0321-4.
23. Li B., Wang H., Dai J., Ji J., Qian W., Zhang D., Hou S., and Guo Y. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Immunology 116 (2005) 487-498
24. Kabat E.A., Wu T.T., Perry H.M., Gottesman K.S., and Foeller C. Sequences of Proteins of Immunological Interest. Fifth ed. (1991), United States Department of Health and Human Services, Bethesda, MD
25. Wright A., Shin S.U., and Morrison S.L. Genetically engineered antibodies: progress and prospects. Crit. Rev. Immunol. 12 (1992) 125-168
26. Nakatani T., Lone Y.C., Yamakawa J., Kanaoka M., Gomi H., Wijdenes J., and Noguchi H. Humanization of mouse anti-human IL-2 receptor antibody B-B10. Protein Eng. 7 (1994) 435-443
27. Kipriyanov S.M., and Le Gall F. Generation and production of engineered antibodies. Mol. Biotechnol. 26 (2004) 39-60
28. Ohtomo T., Tsuchiya M., Sato K., Shimizu K., Moriuchi S., Miyao Y., Akimoto T., Akamatsu K., Hayakawa T., and Ohsugi Y. Humanization of mouse ONS-M21 antibody with the aid of hybrid variable regions. Mol. Immunol. 32 (1995) 407-416
29. Presta L.G., Lahr S.J., Shields R.L., Porter J.P., Gorman C.M., Fendly B.M., and Jardieu P.M. Humanization of an antibody directed against IgE. J. Immunol. 151 (1993) 2623-2632